<DOC>
	<DOCNO>NCT00714493</DOCNO>
	<brief_summary>The purpose study assess effectiveness treatment patient active rheumatoid arthritis inadequate response least 3 month treatment etanercept adalimumab addition methotrexate .</brief_summary>
	<brief_title>RESTART C0168Z05 Rheumatoid Arthritis Study</brief_title>
	<detailed_description>This Phase 4 , multi center , open-label , assessor blind , switch study infliximab patient active rheumatoid arthritis receive methotrexate inadequate response current treatment etanercept adalimumab . The last dose etanercept must least 1 week 2 week prior first infliximab study infusion . The last dose adalimumab must administer least 2 week 4 week prior first infliximab study infusion . The study conduct 30 week include 200 patient . All eligible patient receive 3 mg/kg infliximab infusion ( drug give vein ) week 0 , 2 , 6 every 8 week thereafter , achieve European League Against Rheumatism ( EULAR ) response current dose infliximab . Patients achieve EULAR response increase dose 3mg/kg 5 mg/kg week 14 . Patients achieve EULAR response week 22 increase either 3 mg/kg 5 mg/kg 5mg/kg 7 mg/kg . The last study infusion take place week 22 . The last study visit effectiveness evaluation take place week 26 . A week 30 follow-up visit perform adverse event tuberculosis evaluation , health economics assessment , review concomitant medication . All patient end study early required complete assessment . Patients receive 3 mg/kg infliximab infusion week 0 , 2 , 6 . If patient achieve European League Against Rheumatism ( EULAR ) response , remain current dose . Patients demonstrate EULAR response increase infliximab dose 3 mg/kg 5 mg/kg week 14 . At week 22 , patient also increase infliximab dose 3 mg/kg 5mg/kg 5 mg/kg 7mg/kg demonstrate EULAR response .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients must rheumatoid arthritis Patients must great equal 6 tender joint great equal 6 swollen joint Patients must inadequate disease response etanercept adalimumab Patients must receive etanercept adalimumab combination methotrexate minimum least 3 month prior screen visit . The last dose etanercept must give least 1 week 2 week prior first infliximab infusion . The last dose adalimumab must administer least 2 week 4 week prior first infliximab infusion . Patients history latent active TB Have inflammatory disease rheumatoid arthritis Have chronic recurrent infectious disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>remicade</keyword>
	<keyword>infliximab</keyword>
	<keyword>Centocor</keyword>
	<keyword>etanercept</keyword>
	<keyword>enbrel</keyword>
	<keyword>adalimumab</keyword>
	<keyword>humira</keyword>
	<keyword>restart</keyword>
	<keyword>swollen joint</keyword>
	<keyword>tender joint .</keyword>
</DOC>